Entering text into the input field will update the search result below

Cellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Q4 2019 Earnings Conference Call February 28, 2020 4:30 PM ET

Company Participants

Derrick Li – Head-Strategy and Investor Relations

Tony Liu – Chief Executive Officer and Chief Financial Officer

Conference Call Participants

Madhu Kumar – Baird


Greetings. Welcome to the Cellular Biomedicine Group Fourth Quarter 2019 Earning Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.

I would now like to turn the conference over to your host Derrick Li, Head of Strategy and Investor Relations. Thank you. You may begin.

Derrick Li

Good afternoon and thank you to everyone for joining us today. Speaking today is Cellular Biomedicine Group’s Chief Executive Officer and Chief Financial Officer, Tony Liu. After he completes his fourth quarter 2019 annual update, we will open the call to questions.

Please note that some of the information you’ll hear during our discussion today will consist of forward-looking statements including without limitation those regarding revenue, gross margin, operating expenses, other income and expenses, taxes, capital allocation, timing and outcome of clinical trials and approvals, future operational changes and future business outlook. Actual results or trends could differ materially from our forecast. For more information, please refer to the risk factors discussed in CBMG’s most recently filed current report on Form 10-K and Form 10-Q. Cellular Biomedicine Group assumes no obligation to update any forward-looking statement or information, which speak as of their respective dates.

I’d now like to turn the call over to Tony for introductory remarks.

Tony Liu

Tank you, Derrick and thank you everyone for joining us today. 2019 was an exciting year for Cellular Biomedicine Group. We are expanding our footprint in Maryland. We are renovating a 22,000 square foot facility in Rockville. This expansion is to further expand our research and development capabilities and to support clinical

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.